Hostname: page-component-77f85d65b8-2tv5m Total loading time: 0 Render date: 2026-03-28T15:22:00.896Z Has data issue: false hasContentIssue false

Cognitive analytic therapy at 30

Published online by Cambridge University Press:  02 January 2018

Rights & Permissions [Opens in a new window]

Summary

Cognitive analytic therapy (CAT) was formalised in 1984 by Anthony Ryle. It facilitated the clinical integration of psychodynamic therapy and personal construct/cognitive psychology. It is a brief, user-friendly relational therapy, applicable to the wide range of psychological problems typically seen in public mental health settings. It has recently been included in national guidelines for the treatment of personality disorder in the National Health Service. CAT provides a coherent model of development and psychopathology, which centrally views the self as both socially formed and embedded. Owing to its core relational grounding, CAT is being increasingly applied to team contexts/systems, enabling a ‘common language’ for team formulation/practice. It is also being successfully delivered as a group therapy. This article describes the development and unique features of the CAT model, analyses the current evidence base and identifies potential future directions for the model.

LEARNING OBJECTIVES

  1. Be able to describe the core principles of the CAT approach.

  2. Appreciate the evidence base for CAT.

  3. Understand CAT's place today among talking therapies.

Information

Type
Article
Copyright
Copyright © The Royal College of Psychiatrists 2014 
Figure 0

FIG 1 Narcissistic personality disorder: a mapping showing two of the common self-states.

Figure 1

TABLE 1 Disorder, outcome studies and methodologies in the cognitive analytic therapy outcome evidence base

Figure 2

FIG 2 Forest plot showing uncontrolled effect sizes for the CAT outcome studies. n, number of participants in the study; % weight, the weighting (based on sample size) of each study towards the overall effect size. The plot shows a measure of effect (i.e. an odds ratio, represented by a square) for each of the studies, with confidence intervals (CIs) represented by horizontal lines. The overall meta-analysed index of clinical effectiveness is represented by the vertical dashed line; the vertical solid line represents when there is no clinical effect. This meta-analysed index is also plotted as a diamond, the lateral points of which indicate CIs for this estimate. Should the horizontal CI line for a particular study meet the vertical solid line, it demonstrates that at a given level of confidence, the effect size does not differ from ‘no effect’. If the lateral points of the diamond overlap the vertical solid line, then the overall meta-analysed result also cannot be said to differ from ‘no effect’ at the given level of confidence. The heterogeneity chi-squared was non-significant (F = 4.24, d.f. = 11, P = 0.962), indicating that the studies were homogeneous. The variation in effect size attributable to heterogeneity I2 = 0.00%, and the test of effect size = 0; z = 9.70, P < 0.001.

Figure 3

FIG 3 Funnel plot of the CAT evidence with pseudo-95% confidence limits.

Submit a response

eLetters

No eLetters have been published for this article.